Viridian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viridian Therapeutics (VRDN).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

1S.Buy

15Buy

2Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$37Upside to Avg. PT+59.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$35→$36
Aug 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$38→$39
Jun 30, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$34→$35
Jun 30, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$35→$38
Jun 30, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$32→$43
Jun 30, 2026	Needham	Serge Belanger	PT Raise	Buy	$32→$34
Jun 29, 2026	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$20→$31
Jun 29, 2026	Needham	Serge Belanger	Maintained	Buy	$32
May 15, 2026	Evercore ISI Group	Maneka Mirchandaney	PT Cut	Outperform	$27→$26
May 6, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$30→$34
May 5, 2026	Needham	Serge Belanger	Maintained	Buy	$32
Apr 21, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$36→$33
Apr 8, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$37→$31
Apr 7, 2026	Goldman Sachs	Richard Law	PT Cut	Buy	$36→$31
Apr 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$42→$30
Apr 2, 2026	Evercore ISI Group	Maneka Mirchandaney	PT Cut	Outperform	$45→$32
Mar 31, 2026	Goldman Sachs	Richard Law	PT Cut	Buy	$41→$36
Mar 31, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$44→$37
Mar 31, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$29→$20
Mar 31, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$34→$22

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $32 to $34.

Benzinga Newsdesk

Viridian Therapeutics Inc

Viridian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

PRO
Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34

People Also Watch

People Also Watch

Benzinga

Benzinga

Viridian Therapeutics Inc

Viridian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

PROTruist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

PROTruist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

PROWedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

PRONeedham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

PRO
Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34